Market Newsdesk

New independent board member brings deep MedTech and algorithm design expertise

Wilmington, DE and Ashdod, Israel, Dec. 17, 2020 (GLOBE NEWSWIRE) — Integrity Applications, Inc. (www.integrity-app.com) (OTCQB: IGAP), innovator of GlucoTrack^®, a non-invasive device for measuring glucose levels in people with Type 2 diabetes and prediabetes, announced today that Paul V. Goode has been appointed to the Company’s Board of Directors, effective immediately.

Paul is a highly accomplished medical device professional with extensive experience in product development, from initial concept to global commercialization. Paul currently serves as Vice President of Product Development at Orchestra Biomed where he oversees development of its implantable cardiac stimulator system for hypertension. Prior to Orchestra, Paul served in several executive roles at EndoStim, including Senior Vice President of R&D, Chief Technology Officer, and Interim CEO, and as Director of Engineering at Impulse Dynamics. Additionally, Paul spent years working with diabetes management technologies, including as Vice President of R&D at MetaCure, a neurostimulator device for Type 2 diabetes, as Director of Engineering and Algorithm Development at DexCom, a global continuous glucose monitoring company, and as Senior Engineer at insulin pump and continuous glucose sensor maker, MiniMed, Inc., prior to its acquisition by Medtronic. Paul received his BS, MS and PhD degrees from North Carolina State University, and is a named inventor on over 150 issued patents.

“We are delighted to welcome Paul to Integrity’s Board,” said Allen Danzig, a member of Integrity’s Board of Directors and Chair of the Nominating, Governance and Compensation Committee. “Paul’s vast experience with medical devices, specifically with product development and algorithm design for novel diabetes related devices, will be tremendously beneficial as we bring our transformative technologies to those suffering from prediabetes and diabetes.”

“I am thrilled to be joining the Integrity board and excited to be adding my knowledge and experience to the team driving their mission, said Mr. Goode. “I am impressed by the technology, and I’m particularly looking forward to helping advance the GlucoTrack platform towards the next generation wireless device and into a product that can improve the quality of life for so many. “

About GlucoTrack^®

GlucoTrack^® is a truly non-invasive monitoring device that rapidly measures and displays an individual’s glucose level in about a minute without finger pricking or any pain. GlucoTrack^® features an ear clip with sensors that clips to the earlobe and measures the user’s glucose level using innovative and patented sensor technologies. The measured signals are analyzed using a proprietary algorithm and then a calculated glucose level is displayed on a small handheld device the size of a small mobile phone. The glucose results are stored in the device and used to estimate HbA1c level using a proprietary algorithm. The device can also display glucose values graphically, enabling the user to monitor glucose levels over time. GlucoTrack^® has received approvals for CE Mark in Europe and from the Ministry of Food and Drug Safety in South Korea for type 2 diabetes and prediabetes and is currently available in selected markets in Europe and Asia.

About Integrity Applications, Inc.

Integrity Applications, Inc. (OTCQB: IGAP) was founded in 2001 and is focused on the design, development, and commercialization of non-invasive glucose monitoring technologies for people with type 2 diabetes and prediabetes. The Company has developed GlucoTrack^®, a proprietary non-invasive glucose monitoring device designed to obtain glucose level measurements in about a minute without the pain, incremental cost, difficulty, or discomfort of conventional invasive finger stick devices. Integrity Applications Inc. is a Delaware corporation, with headquarters in the United States and an R&D site in Ashdod, Israel. For more information, please visit http://www.integrity-app.com/ and http://www.glucotrack.com.

Investor Contact: [email protected]
Media Contact: [email protected]

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “expect”, “plan” and “will” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect Integrity Applications’ actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Integrity Applications’ results include, but are not limited to, the ability of Integrity Applications to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including FDA approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to its current and future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Integrity Applications’ filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the SEC on April 14, 2020.

SEATTLE, Dec. 17, 2020 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (the “Company” or “Atossa”), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced today that it has entered into a securities purchase agreement with institutional investors to purchase approximately $14.0 million of its common stock in a registered direct offering priced at-the-market under Nasdaq rules and warrants to purchase common stock in a concurrent private placement. The combined purchase price for one share of common stock and 0.75 warrants to purchase one share of common stock will be $1.00.

Under the terms of the securities purchase agreement, the Company has agreed to sell 14,000,000 shares of common stock. In a private placement, which will be consummated concurrently with the Offering, the Company also has agreed to issue warrants to purchase up to an aggregate of 10,500,000 shares of common stock. The warrants will be immediately exercisable, will expire in 4 and a half years from the date of issuance and will have an exercise price of $1.00 per share.

The gross proceeds to the Company from the registered direct offering and concurrent private placement are estimated to be approximately $14.0 million before deducting the placement agent’s fees and other estimated offering expenses. The offering is expected to close on or about December 21, 2020, subject to the satisfaction of customary closing conditions.

Maxim Group LLC is acting as the sole placement agent for the offering.

The shares of common stock are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333- 248555) previously filed and declared effective by the Securities and Exchange Commission (the “SEC”) on September 10, 2020. The offering of the shares of common stock will be made only by means of a prospectus supplement that forms a part of the registration statement. A prospectus supplement relating to the shares of common stock will be filed with the SEC. When available, copies of the prospectus supplement relating to the registered direct offering, together with the accompanying prospectus, can be obtained at the SEC’s website at www.sec.gov or from Maxim Group LLC, 405 Lexington Avenue, New York, NY 10174, Attention: Syndicate Department, or via email at [email protected] or telephone at (212) 895-3745.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19. For more information, please visit www.atossatherapeutics.com.

Forward-Looking Statements Disclaimer Statement

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and the anticipated use of proceeds from the offering, the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Company Contact:
Atossa Therapeutics, Inc.
Kyle Guse CFO and General Counsel
Office: 866 893-4927
[email protected]

Investor Relations Contact:
Core IR
Office:(516) 222-2560
[email protected]

ATHENS, Greece, Dec. 17, 2020 (GLOBE NEWSWIRE) — Star Bulk Carriers Corp. (the “Company” or “Star Bulk”) (Nasdaq: SBLK) a global shipping company focusing on the transportation of dry bulk cargoes announced today that it has entered into a  definitive agreement with entities affiliated with E.R. Capital Holding GmbH & Cie. KG (“E.R.”  or “Sellers” ) pursuant to which the Company will acquire three (3) cape size  dry bulk vessels , namely  E.R. BAYONNE, E.R. BUENOS AIRES and E.R. BORNEO (the “Vessels”). The Vessels are retrofitted with exhaust gas cleaning systems (Scrubbers). Consideration for the acquisition is payable in the form of $39.0 million in cash (“Cash Consideration”) and 2,100,000 common shares of Star Bulk (“Share Consideration”). The transaction was negotiated by the Company on the basis of NAV.

The Company is in advanced discussions with a leading financial institution to finance the Cash Consideration through proceeds of a five-year term loan.

Below are the details of   the Vessels to be acquired from E.R.:

The Vessels are expected to be delivered to the Company by early February 2021 and delivery remains subject to the execution of customary closing conditions.

About Star Bulk

Star Bulk is a global shipping company providing worldwide seaborne transportation solutions in the dry bulk sector. Star Bulk’s vessels transport major bulks, which include iron ore, coal and grain, and minor bulks, which include bauxite, fertilizers and steel products. Star Bulk was incorporated in the Marshall Islands on December 13, 2006 and maintains executive offices in Athens, Oslo, New York, Cyprus and Singapore. Its common stock trades on the Nasdaq Global Select Market under the symbol “SBLK”. Star Bulk operates a fleet of 119 vessels, with an aggregate capacity of 13.4 million dwt, consisting of 17 Newcastlemax, 22 Capesize, 2 Mini Capesize, 7 Post Panamax, 35 Kamsarmax, 2 Panamax, 17 Ultramax and 17 Supramax vessels with carrying capacities between 52,425 dwt and 209,537 dwt.

Forward-Looking Statements

Matters discussed in this press release may constitute forward looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts.

The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “believe,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” “plan,” “potential,” “may,” “should,” “expect,” “pending” and similar expressions identify forward-looking statements.

The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, examination by the Company’s management of historical operating trends, data contained in its records and other data available from third parties. Although the Company believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond the Company’s control, the Company cannot assure you that it will achieve or accomplish these expectations, beliefs or projections.

In addition to these important factors, other important factors that, in the Company’s view, could cause actual results to differ materially from those discussed in the forward-looking statements include general dry bulk shipping market conditions, including fluctuations in charterhire rates and vessel values; the strength of world economies; the stability of Europe and the Euro; fluctuations in interest rates and foreign exchange rates; changes in demand in the dry bulk shipping industry, including the market for our vessels; changes in our operating expenses, including bunker prices, dry docking and insurance costs; changes in governmental rules and regulations or actions taken by regulatory authorities; potential liability from pending or future litigation; general domestic and international political conditions; potential disruption of shipping routes due to accidents or political events; the availability of financing and refinancing; our ability to meet requirements for additional capital and financing to complete our newbuilding program and grow our business; the impact of the level of our indebtedness and the restrictions in our debt agreements; vessel breakdowns and instances of off‐hire; risks associated with vessel construction; potential exposure or loss from investment in derivative instruments; potential conflicts of interest involving our Chief Executive Officer, his family and other members of our senior management and our ability to complete acquisition transactions as planned. Please see our filings with the Securities and Exchange Commission for a more complete discussion of these and other risks and uncertainties. The information set forth herein speaks only as of the date hereof, and the Company disclaims any intention or obligation to update any forward‐looking statements as a result of developments occurring after the date of this communication.

COS COB, Conn., Dec. 17, 2020 (GLOBE NEWSWIRE) — Chicken Soup for the Soul Entertainment (Nasdaq: CSSE) one of the largest operators of streaming advertising-supported video-on-demand (AVOD) networks announced today the U.S. premiere of the Crackle original series Insomnia, launching on Friday, January 1^st.

From Executive Producer and Director Slava N. Jakovleff (Siberia, The Birthright) and Executive Producer Michael Ohoven (Capote, Rica Famosa Latina, Push), the series stars Shaun Sipos (The Vampire Diaries, Melrose Place), Dylan Everett (Supernatural, DeGrassi: The Next Generation), Pasha Lychnikoff (Shameless, Deadwood), and Alex Jay, who will make her debut.

Set in the streets of Moscow, Russia, the eight-part series chronicles the story of 20 strangers from around the globe who are forced to play the ultimate game of life and death. There can only be one winner and time is of the essence. Injected with a poison that will stop their heart if they fall asleep, contestants must kill or be killed for the antidote and a new life.

“Insomnia combines chilling suspense with nonstop action that our audience will love,” said Philippe Guelton, president of Crackle Plus. “We are thrilled to add this sci-fi series to Crackle’s growing slate of original programming.”

As one of the only AVODs continually adding original and exclusive programming, Crackle adds Insomnia alongside original and exclusive titles that can only be found on Crackle, including Elliot: The Littlest Reindeer, A Reindeer’s Journey, Lennox Lewis: The Untold Story, Robert the Bruce, Spides, Cleanin’ Up the Town: Remembering Ghostbusters, On Point, The Clearing, Corporate Animals, and Going From Broke, which was recently picked up for a second season.

Insomnia
is distributed in the United States by Screen Media, a Chicken Soup for the Soul Entertainment company, and the supplier of exclusive and original content for Crackle Plus.

Crackle linear and VOD networks are available in the U.S. and can be accessed on 29 devices and services including Amazon FireTV, RokuTV, Apple TV, Smart TVs (Samsung, LG, Vizio), gaming consoles (PS4 and XBoxOne), Plex, iOS and Android mobile devices and on desktops at Crackle.com. Crackle is also available in approximately 500,000 hotel rooms in the Marriott Bonvoy chain.

ABOUT CHICKEN SOUP FOR THE SOUL ENTERTAINMENT

Chicken Soup for the Soul Entertainment, Inc. (Nasdaq: CSSE) operates streaming video-on-demand networks (VOD). The company owns a majority stake in Crackle Plus, a company formed with Sony Pictures Television, which owns and operates a variety of ad-supported and subscription-based VOD networks including Crackle, Popcornflix, Popcornflix Kids, Truli, Pivotshare, Españolflix and FrightPix. The company also acquires and distributes video content through its Screen Media subsidiary and produces original long and short-form content through Landmark Studio Group, its Chicken Soup for the Soul Originals division and APlus.com. Chicken Soup for the Soul Entertainment is a subsidiary of Chicken Soup for the Soul, LLC, which publishes the famous book series and produces super-premium pet food under the Chicken Soup for the Soul brand name.

FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks (including those set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Report on Form 10-Q for the nine-month period ended September 30, 2020) and uncertainties which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Investors should realize that if our underlying assumptions for the projections contained herein prove inaccurate or that known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections.

INVESTOR RELATIONS
Taylor Krafchik
Ellipsis
[email protected]
(646) 776-0886

MEDIA CONTACT
Kate Barrette
RooneyPartners LLC
[email protected]
(212) 223-0561

New York, New York, Dec. 17, 2020 (GLOBE NEWSWIRE) — Daniels Corporate Advisory Company (OTC: “DCAC”) Opportunities worked on the last several months are delivering promising results. These new inroads to growth, now acceptable to third party capital providers are possible by the visibility the overall Company is receiving from our Transportation Services subsidiary, Payless Truckers Inc.

For the month of October, Payless had total income of $270,820 that generated Gross Profit of $108,845. Our Program Trucks generated $75,291 of that amount in truck rental income and make ready fees for our fleet and contributed to a Net Profit of $32,026 for the month. The November results will be released shortly. In November we added an additional ten trucks to the fleet bringing our fleet to a total of 18 trucks generating an estimated monthly rental income of approximately $58,500 before debt service payments to our private equity lenders and a five percent maintenance reserve.

Negotiations are continuing with all the parties that were mentioned in our last press release. We expect to conclude most of these deals by year end. During the rest of this month, as we close on the most important we will update shareholders. These relationships include the formal announcement of our deal with Ihander International (the Think Tank) and the potential it adds to the expansion of the Daniels corporate strategy model as an incubator of promising start-ups or early-stage companies. Our discussions included the review of additional concepts for a second subsidiary. This broader view of the Company aided by the addition of another subsidiary creates opportunities for the entire company to attract additional funding from sources that are more long term in nature.

Safe Harbor for Forward-Looking Statements:

The statements above regarding the Company’ s expectations, its operations and certain other matters discussed in this press release may constitute forward-looking statements within the meaning of the federal securities laws and are subject to risks and uncertainties For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see Daniels Corporate Advisory Co. Inc. filings with the Securities and Exchange Commission, including the Company’s most recent reports on Form 10-K and 10-Q, and other SEC filings.

Press Release Contact:
Nicholas Viola
CEO
Email: [email protected]